Jim Cramer on Vertex (VRTX): “A Revolutionary Anti-Pain Drug”
We recently published a list of Jim Cramer Discusses These 10 Stocks & Says US Faces Unfairly High Tariffs Abroad. In this ...
Where Will Vertex Pharmaceuticals Be in 10 Years?
Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic ...
BioSpace3d
Purdue Files for Bankruptcy Anew to Support $7.4B+ Opioid Settlement
The Supreme Court last year blocked a previous settlement proposal from Purdue, arguing that the plan would afford the ...
3 Unstoppable Stocks You Can Buy Now Without Any Hesitation
Novo Nordisk is a great pick to buy with the stock near its 52-week low. Vertex Pharmaceuticals is helping patients and ...
CervoMed: Extension Study Data In Dementia With Lewy Bodies Is Potentially Exciting, With Caveats
CervoMed's stock soars 400% on promising dementia drug data. See more on insights, potential concerns, and what it means for ...
$100 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth This Much Today
Buying $100 In VRTX: If an investor had bought $100 of VRTX stock 5 years ago, it would be worth $253.80 today based on a ...
GEN - Genetic Engineering and Biotechnology News3d
From Tools to Trials: Editing Therapy Companies Pivot to Development
A pair of privately-held developers of editing-based therapies have some successes to show for their recent efforts to ...
Nasdaq12d
Where Will Vertex Pharmaceuticals Be in 10 Years?
The past decade has been a game-changing one for Vertex Pharmaceuticals (NASDAQ: VRTX). The biotech won approval for its first cystic fibrosis (CF) drug -- Kalydeco -- back in 2012 and has since ...